Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Egetis Therapeutics in connection with directed share issuances
Mandate

Vinge has advised Egetis Therapeutics in connection with directed share issuances

October 03, 2024

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with directed share issuances whereby Egetis Therapeutics receives gross proceeds of SEK 300 million.

The share issuances were directed to a number of international and Swedish institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is subject to approval by an extraordinary general meeting as well as approval and publication of a prospectus.

Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi and Karin Karsten.

Related

Vinge advises Revivo Group on the acquisition of Solidenergy

 Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised management of atNorth in connection with the sale of atNorth to CPP Investments and Equinix

 Vinge has advised management of atNorth on the sale of atNorth to Canada Pension Plan Investment Board (CPP Investments) and Equinix (EMEA) Management, Inc. from Partners Group and the minority shareholders.
March 02, 2026

Vinge advises Bain Capital on its majority investment in the Tingstad group

 Vinge, together with Kirkland & Ellis, has advised Bain Capital in acquiring a majority stake in Aktiebolaget Tingstad Papper (“Tingstad”) and its subsidiaries.
March 02, 2026